Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation

Efficacy, Safety and Quality of Life of Palifermin on Reducing Oral Mucositis in Patients With Hematopoietic Stem Cell Transplantation, Prospective Double-blind Randomized Phase III Trial

The purpose of this study is to compare the efficacy and safety of palifermin on reducing mucositis for patients receiving autologous or allogeneic stem cell transplantation with supportive care.

Inclusion Criteria:

• adequate organ function
• patients who will receive autologous stem cell transplantation
• patients who will receive allogeneic stem cell transplantation using myeloablative conditioning regimen

Exclusion Criteria:

• presence of concomitant malignancy
• presence of active infection or oral mucositis prior to stem cell transplantation
• any conditions where the severity of oral mucositis cannot be evaluated